DVAX
Price
$10.99
Change
-$0.20 (-1.79%)
Updated
Aug 7, 04:31 PM (EDT)
Capitalization
1.62B
Earnings call today
ESPR
Price
$1.79
Change
-$0.13 (-6.77%)
Updated
Aug 7, 04:32 PM (EDT)
Capitalization
495.94M
90 days until earnings call
Interact to see
Advertisement

DVAX vs ESPR

Header iconDVAX vs ESPR Comparison
Open Charts DVAX vs ESPRBanner chart's image
Dynavax Technologies
Price$10.99
Change-$0.20 (-1.79%)
Volume$2.18K
Capitalization1.62B
Esperion Therapeutics
Price$1.79
Change-$0.13 (-6.77%)
Volume$3.1K
Capitalization495.94M
DVAX vs ESPR Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. ESPR commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a StrongBuy and ESPR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (DVAX: $11.19 vs. ESPR: $1.92)
Brand notoriety: DVAX and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 58% vs. ESPR: 195%
Market capitalization -- DVAX: $1.62B vs. ESPR: $495.94M
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ESPR is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 4 TA indicator(s) are bullish while ESPR’s TA Score has 4 bullish TA indicator(s).

  • DVAX’s TA Score: 4 bullish, 6 bearish.
  • ESPR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than DVAX.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а +0.18% price change this week, while ESPR (@Pharmaceuticals: Other) price change was +36.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.37%. For the same industry, the average monthly price growth was +7.40%, and the average quarterly price growth was +82.11%.

Reported Earning Dates

DVAX is expected to report earnings on Aug 07, 2025.

ESPR is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.37% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DVAX($1.62B) has a higher market cap than ESPR($496M). DVAX (-12.373) and ESPR (-12.727) have similar YTD gains . DVAX has higher annual earnings (EBITDA): 9.67M vs. ESPR (-150.11M). DVAX has more cash in the bank: 742M vs. ESPR (82.2M). DVAX (257M) and ESPR (266M) have identical debt. DVAX has higher revenues than ESPR: DVAX (232M) vs ESPR (116M).
DVAXESPRDVAX / ESPR
Capitalization1.62B496M327%
EBITDA9.67M-150.11M-6%
Gain YTD-12.373-12.72797%
P/E Ratio31.63N/A-
Revenue232M116M200%
Total Cash742M82.2M903%
Total Debt257M266M97%
FUNDAMENTALS RATINGS
DVAX vs ESPR: Fundamental Ratings
DVAX
ESPR
OUTLOOK RATING
1..100
8024
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
5038
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (38) in the Biotechnology industry is somewhat better than the same rating for DVAX (71). This means that ESPR’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

DVAX's SMR Rating (94) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (38) in the Biotechnology industry is in the same range as DVAX (50). This means that ESPR’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's P/E Growth Rating (97) in the Biotechnology industry is in the same range as ESPR (100). This means that DVAX’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXESPR
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
78%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIQBX11.83N/A
N/A
Morgan Stanley Inst International Eq A
BCLPX8.53N/A
N/A
BlackRock Event Driven Equity Inv C
GISOX18.10N/A
N/A
Grandeur Peak Intl Stalwarts Inv
GMVIX16.48N/A
N/A
Goldman Sachs Small/Mid Cap Equity Inv
UPAAX14.84N/A
N/A
Upright Assets Allocation Plus

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.36%
ACET - DVAX
39%
Loosely correlated
-2.64%
SUPN - DVAX
37%
Loosely correlated
+13.08%
SNDL - DVAX
35%
Loosely correlated
+1.81%
ESPR - DVAX
33%
Loosely correlated
+18.52%
AMRX - DVAX
33%
Poorly correlated
-0.98%
More

ESPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with DVAX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then DVAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+18.52%
DVAX - ESPR
33%
Loosely correlated
+0.36%
ALKS - ESPR
31%
Poorly correlated
-0.19%
AQST - ESPR
30%
Poorly correlated
+1.27%
AMPH - ESPR
29%
Poorly correlated
-2.89%
AMRX - ESPR
28%
Poorly correlated
-0.98%
More